Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the ...

SunMo demonstrated superior progression-free survival and overall response for mosunetuzumab plus polatuzumab vedotin versus ...

ADC Therapeutics (ADCT) lost more than 50% in the premarket on Thursday as Wall Street reacted to topline data from a ...

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs ...

In an ongoing Phase 1 study of 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, Legend Biotech's CAR-T cell therapy LB2501 demonstrated a 100% objective response rate and an 83% ...

Bristol Myers Squibb (NYSE:BMY) has secured approval from the European Commission for the use of Opdivo (nivolumab) in ...

Analysts suggested the deaths could overshadow the PFS results, and the safety trade-off may make it harder for ADC ...

Patients with T-cell acute lymphoblastic leukaemia (T-ALL) and the closely related peripheral T-cell lymphoblastic lymphoma ...

Incyte (INCY) stock is in focus as Xencor (XNCR)-partnered lymphoma drug Monjuvi, as part of a combination regimen, lifts cancer-free survival by 25%. Read more here.

Golcadomide plus standard-of-care chemoimmunotherapy shows potential in improving cure rates among patients with newly ...

Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated ...